Despite the use of adjuvant chemotherapy, deferral of postoperative radiotherapy is associated with worse survival in pediatric patients with medulloblastoma.
The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.
Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center sought to assess the effects of treatment for brain tumors in children over 10 years of follow-up.
Precision medicine may help doctors determine the best treatment options for children with rare, aggressive, and advanced cancer. Information from a patient's entire genome helped personalize treatment options for children with cancer, according to a new study.
Children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
Parents of children with cancer appear to need, want, and often access bereavement mental health services after the death of their child.
Modifying pediatric cancer treatments may reduce occurrence of late effects and promoting early detection, indicated data from a 5-year analysis of childhood cancers survivors presented at ASCO 2015.
There has been a 36% increase in the number of pediatric patients who are being treated with proton therapy for cancer.
Gene-regulating drugs may be effective at treating diffuse intrinsic pontine gliomas (DIPG), research indicates.
Certain treatments used to treat children with cancer may increase their risk for obesity later in life.
A series of statistical analyses have identified both the Miami metro area and an area west of the Everglades as having unusually high rates of pediatric cancers.
A recent study examined symptom distress in children living with advanced cancer, and found that a majority experience high symptom distress.
A model was created to address the challenges of educating staff that care for both adult and pediatric patients.
A program improves the transition from pediatric to adult survivorship care has had a 100% increase in referrals.
Treatment guidelines for pediatric Hodgkin lymphoma issued by the International Lymphoma Radiation Oncology Group (ILROG)April 01, 2015
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining use of 3-D computed tomography (CT)-based radiation therapy planning.
Prevalence of childhood cancer survivors is increasing, and those who survived at least 5 years beyond diagnosis have at least one comorbidity.
Breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).
Working with cells taken from children with a rare form of brain cancer, scientists have identified a genetic pathway that may spur cancer cell growth and resistance to anticancer treatment.
Melanoma in some adolescent and adult patients involve many of the same genetic mutations and would likely respond to the same treatment.
Adult survivors of pediatric cancer who underwent brain irradiation at risk for hormone deficienciesFebruary 17, 2015
Adult survivors of pediatric cancer are at risk for developing pituitary hormone deficiencies that may worsen their health and quality of life.
A new method involving the study of genetic micro-variation, rather than the presence of individual mutations, could help identify malignant tumors in children.
A promising target for developing new therapies for children with high-risk neuroblastoma has been found.
Listening to music or audiobooks has a profound impact on postoperative pain perception in children. The benefit is increased when the patients are allowed to choose their own music or stories.
Scientists have developed a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer.
Fluconazole concentration in pediatric patients with cancer and invasive candidiasis is not sufficient for treatment.
When Ewing sarcoma tumors in mice were treated with combination therapy that included drugs from a family of agents developed to fight breast cancer, the tumors disappeared in a majority of test cases.
For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent diseaseOctober 28, 2014
Obese pediatric patients with acute lymphoblastic leukemia (ALL) are more likely to have minimal residual disease.
Weekend hospital admission for pediatric patients with newly diagnosed leukemia is associated with a longer length of stay, slightly longer wait to start chemotherapy, and higher risk for respiratory failure.
This camp offers children, adolescents, and young adults coping with life-threatening illness a chance to enjoy a week of normal summertime activities.
Weekend admission for pediatric patients with leukemia associated with a longer length of stay.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|